AeroVironment Inc. (NASDAQ:AVAV) is one of the most promising mid-cap stocks to buy according to ***** ysts. On June 2, AeroVironment announced plans to invest $15 million to expand its advanced production capabilities in Greene County near Dayton, Ohio. The expansion includes new facilities in Beavercreek and Xenia to support pilot-scale and mid-volume production, including advanced biotechnology manufacturing and defense-related components.
The project is designed to strengthen domestic manufacturing capacity for critical defense and biotechnology programs, with close proximity to the Air Force Research Laboratory /AFRL and Wright-Patterson Air Force Base. The expanded sites will support manufacturing, integration, and testing activities aligned with national security priorities, while also enabling future scale-up into full-rate production.
The investment is expected to create around 200 new jobs and generate significant regional economic impact, supported by state and regional incentive programs. AeroVironment Inc. (NASDAQ:AVAV) emphasized that the expansion is part of a broader strategy to enhance US defense manufacturing capacity, improve supply chain resilience, and accelerate the development of advanced mission-critical technologies.
AeroVironment Inc. (NASDAQ:AVAV) designs and manufactures unmanned aerial vehicles, ground robotic systems, and loitering munitions.
While we acknowledge the potential of AVAV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Most ***** yst rating changes move a single notch. So when one of the more closely followed semiconductor ***** ysts skips the middle rating and jumps two rungs at once, it's worth a closer look -- not necessarily as a reason to buy, but as a window into how the thinking around artificial intelligence (AI) spending may be changing.
That's what happened on June 11, when Bank of America's Vivek Arya double-upgraded Intel (NASDAQ: INTC) to buy from underperform, lifting his price target to $135 from $96. Banks tend to reserve a move like that for moments when the thesis they had been betting against breaks. And it came after Intel had already more than tripled in 2026 -- less a call on a forgotten stock than a bet that the turnaround has further to run.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Intel shares rose about 6% in the following session, closing near $125 as of this writing.
The more useful question isn't whether the target is right. It's what the upgrade says about the next phase of the AI trade.

What happened: Marvell Technology (MRVL) stock surged more than 9% on Monday.
What's behind the move: The semiconductor company, listed on Nasdaq, will officially join the S&P 500 (^GSPC) index on June 22.
Monday morning's gains put Marvell on track to recover much of Friday's losses following a market-wide sell-off. Marvell stock has rallied sharply in recent weeks, fueled in part by comments from Nvidia (NVDA) CEO Jensen Huang, who described the chipmaker as "the next trillion-dollar company.
What else you need to know: The custom chipmaker's market cap sat at around $230 billion on Monday, with shares up nearly 240% year to date.

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) sources and distributes pharmaceutical products. Valued at $53.5 billion by market cap, the company offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to healthcare providers.
Companies worth $10 billion or more are generally described as “large-cap stocks,” and COR effortlessly fits that description, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the medical distribution industry. COR’s strengths come from its strategic role in the healthcare value chain, diversified portfolio, and scale that gives it strong bargaining power. It uses cross-business synergies, brand equity, and a solid balance sheet to drive innovation and operational efficiency. Advanced supply chain and data ****** ytics capabilities support high fill rates and alignment with trends like value-based care and personalized medicine.
Billionaire Charlie Munger Was Asked Why Warren Buffett Is ‘So Much Richer’ Despite Being Partners — ‘Why Was Albert Einstein Poorer Than I Was?’
Ahead of Oracle Earnings, Here's What Barchart Data Says Comes Next for ORCL Stock
Dear Qualcomm Stock Fans, Mark Your Calendars for June 24